Cardiology

Recurrent VTE shows a higher rate than expected for patients with subsegmental pulmonary embolism without proximal deep vein thrombosis managed without anticoagulation.

Dr. Gregory Weiss reviews a recent BMJ article detailing sodium content in processed meats and fish in different countries throughout the world and the implications it could have on cardiovascular health at a national level.

Data show the multivariable-adjusted HR for increase in seafood consumption of 1 oz per day and all-cause mortality was 0.84 and for CVD-related mortality was 0.89.

Our latest cardiology case report from Dr. Brady Pregerson features a woman in her mid-20s presenting to the emergency department with chest pain for the last 24 hours and a slight cough.

Patients with history of VTE, peak D-dimer ≥3 μg/mL, and predischarge CRP ≥10 mg/dL were at high risk of experiencing new onset of VTE after hospital discharge.

November's cardiology month in review features stories from the AHA's late-breaking sessions and Kidney Week 2021.

Patients considered adherent to caFFR had a significantly lower risk of MACE, compared to non-adherent patients (adjusted hazard ratio, 0.33).

Dr. Gregory Weiss offers a breakdown of the recent ESC guidelines for management of cardiovascular disease during the ongoing COVID-19 pandemic, including specific insight into care pathways, treatment, and follow-up.

There was no differences in complications by site in either the left or right subclavian vein.

Undergoing bariatric surgery was associated with reductions in risk of adverse liver outcomes and MACE versus nonsurgical management among patients with obesity and biopsy-proven nonalcoholic steatohepatitis in the SPLENDOR study.

Study data show for each $1,000 decrease in median household income, the number of TAVR procedures performed per 100,000 Medicare beneficiaries was 0.2% lower.

An analysis of data from the SPLENDOR study suggests undergoing baraitric surgery was associated with an 88% reduction in risk of progression of fatty liver to cirrhosis, liver cancer, or liver-related death and a 70% reduction in risk of major adverse cardiovascular events in patients with NASH and obesity.

An analysis of nearly 1000 patients from Spain is providing clinicians with insight into factors that could help predict negative outcomes among patients with stable coronary artery disease.

Data from the SWISS-AF study is providing clinicians with insight into the likelihood of patients to perceive symptoms of atrial fibrillation based on whether or not they had diabetes.

Investigators noted that several types of AID systems improved Time-in-Range and HbA1c with minimal concerns around severe hypoglycemia in type 1 diabetes care.

The treatment was effective across all weight groups.

The latest data from the digital care transformation program provides insight into effects of digital monitoring programs on helping patients achieve blood pressure and cholesterol goals.

More than 90% of patients in hypertension and lipid management accomplished their predetermined goals after completing the remote program.

Every year, AHA Scientific Sessions provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for late-breaking data from AHA 2021 Scientific Sessions includes AVATAR, RAPID CABG, REVERSE-IT, and more.

After 1 year, 37% of patients had died and 65% of patients were readmitted to the hospital.

Bentracimab achieved the predetermined primary endpoint of immediate and sustained reversal of the antiplatelet effects of ticagrelor in the REVERSE-IT trial.

Young smokers in 2017 were more likely to have other comorbid conditions including hypertension, diabetes, and obesity.

A new study from the American Heart Association Scientific Sessions 2021 found that atherosclerotic cardiovascular disease risk increases with sdLDL-C levels, regardless of sex or race.

The ASCEND trial indicates low-dose aspirin use was associated with a nonsignificant reduction in risk of dementia among patients with diabetes and no history of cardiovascular disease.

Data from the ASCEND trial provide clinicians with insight into the risk of dementia based on long-term use of low-dose aspirin among patients with diabetes and no history of cardiovascular disease.